SCHEMBL13342001

SCHEMBL13342001

NC(=O)Cc1csc(NC(=O)c2ccc(Cl)s2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.70
MEN1 O00255 8/20 0.70
F10 P00742 3/20 0.60
F2 P00734 2/20 0.60
LMNA P02545 6/20 0.59
KDM4E B2RXH2 6/20 0.59
NPC1 O15118 5/20 0.59
HTT P42858 4/20 0.59
RAB9A P51151 4/20 0.59
NPSR1 Q6W5P4 3/20 0.59
HSD17B10 Q99714 2/20 0.59
SMN1; SMN2 Q16637 4/20 0.56
HPGD P15428 4/20 0.56
ALOX15 P16050 3/20 0.56
TSHR P16473 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
ALDH1A1 P00352 5/20 0.55
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CSNK2A1 P68400 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539958 0.89 MEN1 (0.71) KMT2AMEN1F10F2LMNA
SCHEMBL3539307 0.82 MEN1 (1.00) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL13341995 0.80 F2 (0.59) KMT2AMEN1F10F2LMNA
SCHEMBL3648974 0.79 MEN1 (0.46) KMT2AMEN1F10F2LMNA
SCHEMBL5717840 0.78 CSNK2A1 (0.57) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL5717620 0.76 KDM4E (0.74) KDM4ENPC1RAB9ASMN1; SMN2CSNK2A1
SCHEMBL8266843 0.76 F10 (1.00) KMT2AMEN1F10F2LMNA
SCHEMBL5717678 0.76 GCK (0.65) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL20787910 0.74 NPC1 (1.00) KMT2AMEN1LMNAKDM4ENPC1
SCHEMBL5717862 0.74 MEN1 (0.69) KMT2AMEN1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718659-B2 Heteroarylacetamide inhibitors of factor Xa HOFFMANN-LA ROCHE INC. (US) 2010-05-18 US disclosed
US-20080146550-A1 HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa BOEHRINGER MARKUS 2008-06-19 US disclosed
US-7361672-B2 Heteroarylacetamide inhibitors of factor Xa HOFFMANN-LA ROCHE INC. (US) 2008-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146550-A1 HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa F12, TFPI, F2 KMT2A 1273/4885MEN1 3926/4885F10 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.